News

This article summarizes recent health news, covering a spectrum of global issues. Highlights include Brazil's avian flu trade ...
Eli Lilly (LLY 1.15%) and Novo Nordisk (NVO 0.14%) are two phenomenal growth stocks that investors probably can't go wrong ...
The Hims & Hers wellness platform announced Wednesday it will soon offer a generic version of the weight loss drug semaglutide in Canada as Novo Nordisk's patent on its branded version, known as ...
Recent health news includes trade restrictions on Brazilian chicken due to bird flu, potential U.S. tariffs on ...
Novo Nordisk is a global diabetes and weight loss leader with strong long-term growth prospects. Read why NVO stock is a ...
Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...
The pharmaceutical industry is criticizing the Trump administration’s plan for carrying out a critical round of Medicare drug ...
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...
Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.
Wall Street hits record highs as payrolls surge. Explore healthcare stock movers, obesity drug breakthroughs, AbbVie deals, Centene struggles & ...
Novo Nordisk A/S (NYSE:NVO) ranks among the best set-it-and-forget-it stocks to buy. Novo Nordisk A/S (NYSE:NVO) announced on ...